Rex Bionics' RAPPER II clinical trial interim data were presented at the Australia and New Zealand Spinal Cord Society meeting last week. Trial interim results show that the Rex unit is safe for patient use. Positive RAPPER II results are expected to facilitate the company’s commercialisation strategy for the Rex exoskeleton. We will revisit our forecasts following H1 results in December.
